Last updated: 2026-10-13 13:19:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Profound Medical Corp. (PROF) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $7.22, with a market capitalisation of $252.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.80 to $8.95. This page covers its latest market performance, valuation, price trends and company information.
$252.13M | |
$7.14 | |
$28.97 | |
$3.10 | |
$7.25 | |
377.00 | |
179.32K | |
-- | |
$8.95 | |
$4.80 | |
-- | |
-- |
Profound Medical Corp. (PROF) is trading at $7.22 in pre-market trading as of 2026-10-13 13:15:00, down 0.48% ($0.04) from the previous close of $7.25
Pre-market trading shows how investors are pricing PROF before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Profound Medical Corp. (PROF) moved from $5.84 to $7.22, representing a gain of 23.54% ($1.38).
The stock traded between $5.65 and $7.40 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 638.30 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 58.2%
PROF is currently trading at $7.22, placing it 58.2% of the way from its 52-week low of $4.80 to its 52-week high of $8.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 162 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profound Medical Corp. (PROF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.